HT
Hexamer Therapeutics, Inc
SEC filingBiotechnology · Pullman, WA
Amount raised$500Ksold at filing
Total offering$2.5M$2M still open
Investors in the raise2count reported to the SEC
FiledSep 15, 2026first sale Jul 7, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Robert H BogdenExecutive Officer, Director
Brad H CallDirector
R. Scott H BlackleyDirector
Keith H MillerDirector
Colin H CollinsDirector
Stephen H CrawfordDirector
Executive officers, directors and promoters as listed on the Form D.